Exicure, Inc. Reports Net Loss of $10.2 Million for the First Half of 2023

Exicure, Inc.(XCUR), a leading clinical-st age biotechnology company specializing in developing gene regulatory and immunotherapeutic drugs, has announced its unaudited condensed consolidated financial results for the second quarter and first half of 2023. The financial statements reveal a net loss of $10.2 million for the six-month period ending June 30, 2023, and a significant absence of collaboration revenue compared to the previous year, marking a challenging period for the company.

Net Loss of $10.2 Million Highlights Financial Struggles

Exicure, Inc. faced a net loss of $10.2 million for the first half of 2023, indicating financial challenges during this period. The company's net loss reflects a drop in revenue and higher operating expenses, impacting its overall financial performance.

Collaboration Revenue Absent, Revenue Shows Decline